| Drug General Information |
| Drug ID |
D0M3PV
|
| Former ID |
DNC004117
|
| Drug Name |
L-741626
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Investigative |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C20H21ClN2O
|
| InChI |
InChI=1S/C20H21ClN2O/c21-17-7-5-16(6-8-17)20(24)9-11-23(12-10-20)14-15-13-22-19-4-2-1-3-18(15)19/h1-8,13,22,24H,9-12,14H2
|
| InChIKey |
LLBLNMUONVVVPG-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| PubChem Substance ID |
7448639, 10243417, 11111363, 11113848, 16830225, 17405303, 24278529, 26752021, 29311516, 46500376, 47500597, 47796125, 48095618, 48170513, 48319567, 48395002, 48395003, 50017904, 50104688, 50104689, 53777848, 57309776, 57344600, 77616850, 85209593, 85231104, 85788761, 90341424, 91706398, 92304247, 103133102, 103247487, 103947637, 104380256, 117463128, 121361530, 124749960, 124799409, 124880518, 124880519, 124880520, 124880521, 125541615, 126728225, 128504576, 134341322, 135089330, 135650487, 135698245, 135710054
|
| Target and Pathway |
| Target(s) |
D(3) dopamine receptor |
Target Info |
Inhibitor |
[2]
|
|---|
| D(4) dopamine receptor |
Target Info |
Inhibitor |
[2]
|
| D(2) dopamine receptor |
Target Info |
Inhibitor |
[2]
|
|
KEGG Pathway
|
Neuroactive ligand-receptor interaction
|
|
Dopaminergic synapsehsa04080:Neuroactive ligand-receptor interaction
|
|
Dopaminergic synapsehsa04015:Rap1 signaling pathway
|
|
cAMP signaling pathway
|
|
Gap junction
|
|
Dopaminergic synapse
|
|
Parkinson's disease
|
|
Cocaine addiction
|
|
Alcoholism
|
|
PANTHER Pathway
|
Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
|
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
|
|
Dopamine receptor mediated signaling pathway
|
|
Nicotine pharmacodynamics pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
|
Nicotine pharmacodynamics pathway
|
|
Reactome
|
Dopamine receptors
|
|
G alpha (i) signalling eventsR-HSA-390651:Dopamine receptors
|
|
G alpha (i) signalling events
|
|
WikiPathways
|
Monoamine GPCRs
|
|
GPCRs, Class A Rhodopsin-like
|
|
GPCR ligand binding
|
|
GPCR downstream signaling
|
|
Nicotine Activity on Dopaminergic Neurons
|
|
GPCRs, OtherWP666:Hypothetical Network for Drug Addiction
|
|
Genes and (Common) Pathways Underlying Drug Addiction
|
| References |
| REF 1 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 177). |
|---|
| REF 2 | Synthesis and characterization of selective dopamine D2 receptor antagonists. 2. Azaindole, benzofuran, and benzothiophene analogs of L-741,626. Bioorg Med Chem. 2010 Jul 15;18(14):5291-300. doi: 10.1016/j.bmc.2010.05.052. Epub 2010 May 24. |
|---|
